Meloxicam in the treatment of in vitro and in vivo models of urinary bladder cancer

Biomedicine and Pharmacotherapy

Volumn 67, Issue 4, 2013, Pages 277-284

  Arantes Rodrigues, Regina ^a   Pinto Leite, Rosário ^b   Ferreira, Rita ^c   Neuparth, Maria João ^d   Pires, Maria João ^a   Gaivão, Isabel ^a   Palmeira, Carlos ^e,f   Santos, Lúcio ^e   Colaço, Aura ^a   Oliveira Collins, Paula ^a  

^a UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^b Hospital Center of Tras os Montes and Alto Douro   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d CESPU   (Portugal)

^e PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^f UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Meloxicam; Mice; Urinary bladder cancer cell lines

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATININE; INTERLEUKIN 6; MELOXICAM; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; TUMOR NECROSIS FACTOR ALPHA; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CANCER MODEL; CELL PROLIFERATION; CELL STRUCTURE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; LIVER FUNCTION; MALE; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BUTYLHYDROXYBUTYLNITROSAMINE; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; COMET ASSAY; CYCLOOXYGENASE INHIBITORS; DNA DAMAGE; FLOW CYTOMETRY; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED ICR; MICROSCOPY; NEOPLASMS, EXPERIMENTAL; PRECANCEROUS CONDITIONS; THIAZINES; THIAZOLES; URINARY BLADDER NEOPLASMS;

EID: 84876942646     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.01.010     Document Type: Article

References (31)

1. Kamp D.W., Shacter E., Weitzman S.A. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park) 2011, 25(5):400-410.
2. Ricciotti E., FitzGerald G.A. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011, 31:986-1000.
3. Harris Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 2007, 42:93-126.
4. Compare D., Nardone O., Nardone G. Non-steroidal anti-inflammatory drugs in the carcinogenesis of the gastrointestinal tract. Pharmaceuticals 2010, 3:2495-2516.
5. Sobolewski C., Cerella C., Dicato M., Ghibelli L., Diederich M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol 2010, 2010:215158.
6. Morrison Inflammation and cancer: a comparative view. J Vet Intern Med 2012, 26:18-31.
7. Khan S.A., McLean M.K. Toxicology of frequently encountered nonsteroidal anti-inflammatory drugs in dogs and cats. Vet Clin North Am Small Anim Pract 2012, 42(2):289-306.
8. Bachhav Y.G., Patravale V.B. Formulation of meloxicam gel for topical application: in vitro and in vivo evaluation. Acta Pharm 2010, 60:153-163.
9. Simmons D.L., Botting R.M., Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004, 56:387-437.
10. Kern M.A., Schöneweiss M.M., Sahi D., Bahlo M., Haugg A.M., Kasper H.U., et al. Cyclooxygenase 2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis 2004, 25(7):1193-1199.
11. Montejo C., Barciab E., Negrob S., Fernández-Carballidob A. Effective antiproliferative effect of meloxicam on prostate cancer-cells: development of a new controlled release system. Int J Pharma 2010, 387:223-229.
12. Rouprêt M., Zigeuner R., Palou J., Boehle A., Kaasinen E., Sylvester R., et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 2011, 59(4):584-594.
13. Vasconcelos-Nóbrega C., Pinto-Leite R., Arantes-Rodrigues R., Ferreira R., Brochado P., Cardoso M.L., et al. In vivo and in vitro effects of RAD001 on urinary bladder cancer. Urol Oncol 2011, 10.1016/j.urolonc.2011.11.002.
14. Pinto-Leite R., Arantes-Rodrigues R., Palmeira C., Gaivão I., Cardoso M.L., Colaço A., et al. Everolimus enhances gemcitabine-induced cytotoxicity in urinary bladder cancer-cell lines. J Toxicol Environ Health A 2012, 75(13-15):788-799.
15. Collins The comet assay for DNA damage and repair: principles applications, and limitations. Mol Biotechnol 2004, 26:249-261.
16. Goldman A.P., Williams C.S., Sheng H., Lamps L.W., Williams V.P., Pairet M., et al. Meloxicam inhibits the growth of colorectal cancer-cells. Carcinogenesis 1998, 19(12):2195-2199.
17. Eble J.N., Sauter G., Epstein J.I., Sesterhenn IA, World Health Organization Classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs 2004, IARC Press, Lyon.
18. Koki A.T., Masferrer J.L. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2002, 9(2 Suppl.):28-35.
19. Wolfesberger B., Hoelzl C., Walter I., Reider G.A., Fertl G., Thalhammer J.G., et al. In vitro effects of meloxicam with or without doxorubicin on canine osteosarcoma cells. J Vet Pharmacol Ther 2006, 29(1):15-23.
20. Li J., Chen X., Dong X., Xu Z., Jiang H., Sun X. Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells. J Gastroenterol Hepatol 2006, 21(12):1814-1820.
21. Xin B., Yokoyama Y., Shigeto T., Futagami M., Mizunuma H. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer 2007, 110(4):791-800.
22. Bijnsdorp I.V., van den Berg J., Kuipers G.K., Wedekind L.E., Slotman B.J., van Rijn J., et al. Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells. J Neurooncol 2007, 85(1):25-31.
23. Yamazaki R., Kusonoki N., Matsuzaki T., Hashimoto S., Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 2002, 531:278-284.
24. Hattori K., Iida K., Joraku A., Tsukamoto S., Akaza H., Oyasu R. Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int 2006, 97(3):640-643.
25. Oliveira P.A., Colaço A., Palomino L.F.C., Lopes C. Rat and mouse urothelial carcinogenesis. Exp Pathol Health Sci 2008, 2(1):23-28.
26. Sereno J., Parada B., Reis F., Cunha F.X., Teixeira-Lemos E., Garrido P., et al. Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model. Mediators Inflamm 2010, 380937. 10.1155/2010/380937.
27. Okajima E., Denda A., Ozono S., Takahama M., Akai H., Sasaki Y., et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl) nitrosamine. Cancer Res 1998, 58:3028-3031.
28. Moon R.C., Kelloff G.J., Detrisac C.J., Steele V.E., Thomas C.F., Sigman C.C. Chemoprevention of OH-BBN-induced urinary bladder cancer in mice by piroxicam. Carcinogenesis 1993, 14:1487-1489.
29. D'Arca D., LeNoir J., Wildemore B., Gottardo F., Bragantini E., Shupp-Byrne D., et al. Prevention of urinary urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor. Urol Oncol 2010, 28(2):189-194.
30. Parada B., Sereno J., Reis F., Teixeira-Lemos E., Garrido P., Pinto A.F., et al. Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis. Cancer Biol Ther 2009, 8(17):1615-1622.
31. van Horssen R., Ten Hagen T.L., Eggermont A.M. TNF-alpha in cancer treatment: molecular insights, antitumour effects, and clinical utility. Oncologist 2006, 11(4):397-408.